Treatment of Refractory Ulcerative Necrobiosis Lipoidica Diabeticorum With Infliximab: Report of a Case | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
Observation
April 2009

Treatment of Refractory Ulcerative Necrobiosis Lipoidica Diabeticorum With Infliximab: Report of a Case

Author Affiliations

Author Affiliations: Department of Dermatology, Angiogenesis & Wound Healing Center (Ms Hu and Drs Winterfield and Li) and Dermatology-Rheumatology Center (Dr Qureshi), Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts; and Department of Dermatology, Lahey Clinic, Burlington, Massachusetts (Dr Bevona).

Arch Dermatol. 2009;145(4):437-439. doi:10.1001/archdermatol.2009.6
Abstract

Background  Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus. Skin lesions usually develop on the lower extremities and can progress toward ulceration and scarring. Many treatments have been proposed, but few have demonstrated consistent efficacy, and no standard regimens have emerged to date.

Observations  An 84-year-old woman with type 1 diabetes mellitus presented with a 3-year history of chronic right-lower-extremity erythematous papules and plaques that had developed into confluent ulcers with prominent granulation tissue and an orange-yellow hue. The results of a biopsy of the lesion was consistent with a diagnosis of NLD. The wound did not respond to 4 months of intensive local wound care. After the first intravenous infusion of infliximab (5 mg/kg), there was rapid reduction in wound size, pain, and drainage. There was complete wound healing with excellent cosmesis at 6 weeks (total of 3 infusions).

Conclusions  Infliximab should be considered in the treatment of refractory, ulcerative NLD. Its anti–tumor necrosis factor activity may underlie its efficacy in targeting this granulomatous process, and further investigation should be undertaken to confirm these results.

×